This study compares the classification accuracy of novel transformer-based deep learning models (ViT and BEiT) on brain MRIs of gliomas and meningiomas through a feature-driven approach. Meta's Segment Anything Model was used for semi-automatic segmentation, therefore proposing a total neural network-based workflow for this classification task. ViT and BEiT models were finetuned to a publicly available brain MRI dataset. Gliomas/meningiomas cases (625/507) were used for training and 520 cases (260/260; gliomas/meningiomas) for testing. The extracted deep radiomic features from ViT and BEiT underwent normalization, dimensionality reduction based on the Pearson correlation coefficient (PCC), and feature selection using analysis of variance (ANOVA). A multi-layer perceptron (MLP) with 1 hidden layer, 100 units, rectified linear unit activation, and Adam optimizer was utilized. Hyperparameter tuning was performed via 5-fold cross-validation. The ViT model achieved the highest AUC on the validation dataset using 7 features, yielding an AUC of 0.985 and accuracy of 0.952. On the independent testing dataset, the model exhibited an AUC of 0.962 and an accuracy of 0.904. The BEiT model yielded an AUC of 0.939 and an accuracy of 0.871 on the testing dataset. This study demonstrates the effectiveness of transformer-based models, especially ViT, for glioma and meningioma classification, achieving high AUC scores and accuracy. However, the study is limited by the use of a single dataset, which may affect generalizability. Future work should focus on expanding datasets and further optimizing models to improve performance and applicability across different institutions. This study introduces a feature-driven methodology for glioma and meningioma classification, showcasing advancements in the accuracy and model robustness of transformer-based models.

New imaging techniques appearing over the last few decades have replaced procedures that were uncomfortable, of low specificity, and prone to adverse events. While computed tomography remains useful for imaging patients with seizures in acute settings, structural magnetic resonance imaging (MRI) has become the most important imaging modality for epilepsy evaluation, with adjunctive functional imaging also increasingly well established in presurgical evaluation, including positron emission tomography (PET), single photon ictal-interictal subtraction computed tomography co-registered to MRI and functional MRI for preoperative cognitive mapping. Neuroimaging in inherited metabolic epilepsies is integral to diagnosis, monitoring, and assessment of treatment response. Neurotransmitter receptor PET and magnetic resonance spectroscopy can help delineate the pathophysiology of these disorders. Machine learning and artificial intelligence analyses based on large MRI datasets composed of healthy volunteers and people with epilepsy have been initiated to detect lesions that are not found visually, particularly focal cortical dysplasia. These methods, not yet approved for patient care, depend on careful clinical correlation and training sets that fully sample broad populations.

Introduction and ObjectivesMany women with multiple sclerosis (MS) experience neurogenic overactive bladder (NOAB) characterized by urinary frequency, urinary urgency and urgency incontinence. The objective of the study was to create machine learning (ML) models utilizing clinical and imaging data to predict NOAB treatment success stratified by treatment type. MethodsThis was a retrospective cohort study of female patients with diagnosis of NOAB and MS seen at a tertiary academic center from 2017-2022. Clinical and imaging data were extracted. Three types of NOAB treatment options evaluated included behavioral therapy, medication therapy and minimally invasive therapies. The primary outcome - treatment success was defined as > 50% reduction in urinary frequency, urinary urgency or a subjective perception of treatment success. For the construction of the logistic regression ML models, bivariate analyses were performed with backward selection of variables with p-values of < 0.10 and clinically relevant variables applied. For ML, the cohort was split into a training dataset (70%) and a test dataset (30%). Area under the curve (AUC) scores are calculated to evaluate model performance. ResultsThe 110 patients included had a mean age of patients were 59 years old (SD 14 years), with a predominantly White cohort (91.8%), post-menopausal (68.2%). Patients were stratified by NOAB treatment therapy type received with 70 patients (63.6%) at behavioral therapy, 58 (52.7%) with medication therapy and 44 (40%) with minimally invasive therapies. On MRI brain imaging, 63.6% of patients had > 20 lesions though majority were not active lesions. The lesions were mostly located within the supratentorial (94.5%), infratentorial (68.2%) and 58.2 infratentorial brain (63.8%) as well as in the deep white matter (53.4%). For MRI spine imaging, most of the lesions were in the cervical spine (71.8%) followed by thoracic spine (43.7%) and lumbar spine (6.4%).10.3%). After feature selection, the top 10 highest ranking features were used to train complimentary LASSO-regularized logistic regression (LR) and extreme gradient-boosted tree (XGB) models. The top-performing LR models for predicting response to behavioral, medication, and minimally invasive therapies yielded AUC values of 0.74, 0.76, and 0.83, respectively. ConclusionsUsing these top-ranked features, LR models achieved AUC values of 0.74-0.83 for prediction of treatment success based on individual factors. Further prospective evaluation is needed to better characterize and validate these identified associations.

Foundation Models (FMs) have shown great promise for multimodal medical image analysis such as Magnetic Resonance Imaging (MRI). However, certain MRI sequences may be unavailable due to various constraints, such as limited scanning time, patient discomfort, or scanner limitations. The absence of certain modalities can hinder the performance of FMs in clinical applications, making effective missing modality imputation crucial for ensuring their applicability. Previous approaches, including generative adversarial networks (GANs), have been employed to synthesize missing modalities in either a one-to-one or many-to-one manner. However, these methods have limitations, as they require training a new model for different missing scenarios and are prone to mode collapse, generating limited diversity in the synthesized images. To address these challenges, we propose DiffM⁴RI, a diffusion model for many-to-many missing modality imputation in MRI. DiffM⁴RI innovatively formulates the missing modality imputation as a modality-level inpainting task, enabling it to handle arbitrary missing modality situations without the need for training multiple networks. Experiments on the BraTs datasets demonstrate DiffM⁴RI can achieve an average SSIM improvement of 0.15 over MustGAN, 0.1 over SynDiff, and 0.02 over VQ-VAE-2. These results highlight the potential of DiffM⁴RI in enhancing the reliability of FMs in clinical applications. The code is available at https://github.com/27yw/DiffM4RI.

Accurate detection of cortical infarct is critical for timely treatment and improved patient outcomes. Current brain imaging methods often require invasive procedures that primarily assess blood vessel and structural white matter damage. There is a need for non-invasive approaches, such as functional MRI (fMRI), that better reflect neuronal viability. This study utilized automated machine learning (auto-ML) techniques to identify novel infarct-specific fMRI biomarkers specifically related to chronic cortical infarcts. We analyzed resting-state fMRI data from the multi-center ADNI dataset, which included 20 chronic infarct patients and 30 cognitively normal (CN) controls. This study utilized automated machine learning (auto-ML) techniques to identify novel fMRI biomarkers specifically related to chronic cortical infarcts. Surface-based registration methods were applied to minimize partial-volume effects typically associated with lower resolution fMRI data. We evaluated the performance of 7 previously known fMRI biomarkers alongside 107 new auto-generated fMRI biomarkers across 33 different classification models. Our analysis identified 6 new fMRI biomarkers that substantially improved infarct detection performance compared to previously established metrics. The best-performing combination of biomarkers and classifiers achieved a cross-validation ROC score of 0.791, closely matching the accuracy of diffusion-weighted imaging methods used in acute stroke detection. Our proposed auto-ML fMRI infarct-detection technique demonstrated robustness across diverse imaging sites and scanner types, highlighting the potential of automated feature extraction to significantly enhance non-invasive infarct detection.

Accurate segmentation of brain tumor images, particularly gliomas in MRI scans, is crucial for early diagnosis, monitoring progression, and evaluating tumor structure and therapeutic response. A novel lightweight, transformer-based U-Net model for brain tumor segmentation, integrating attention mechanisms and multi-layer feature extraction via atrous convolution to capture long-range relationships and contextual information across image regions is proposed in this work. The model performance is evaluated on the publicly accessible BraTS 2020 dataset using evaluation metrics such as the Dice coefficient, accuracy, mean Intersection over Union (IoU), sensitivity, and specificity. The proposed model outperforms many of the existing methods, such as MimicNet, Swin Transformer-based UNet and hybrid multiresolution-based UNet, and is capable of handling a variety of segmentation issues. The experimental results demonstrate that the proposed model acheives an accuracy of 98.23%, a Dice score of 0.9716, and a mean IoU of 0.8242 during training when compared to the current state-of-the-art methods.

Widely used in oncology PET, 2-deoxy-2-18F-FDG PET is more accessible and affordable than amyloid PET, which is a crucial tool to determine amyloid positivity in diagnosis of Alzheimer disease (AD). This study aimed to leverage deep learning with residual 3D convolutional neural networks (3DCNN) to develop a robust model that predicts amyloid-β positivity by using FDG-PET. In this study, a cohort of 187 patients was used for model development. It consisted of patients ranging from cognitively normal to those with dementia and other cognitive impairments who underwent T1-weighted MRI, 18F-FDG, and 11C-Pittsburgh compound B (PiB) PET scans. A residual 3DCNN model was configured using nonexhaustive grid search and trained on repeated random splits of our development data set. We evaluated the performance of our model, and particularly its robustness, using a multisite data set of 99 patients of different ethnicities with images at different site harmonization levels. Our model achieved mean AUC scores of 0.815 and 0.840 on images without and with site harmonization correspondingly. Respectively, it achieved higher AUC scores of 0.801 and 0.834 in the cognitively normal (CN) group compared with 0.777 and 0.745 in the dementia group. As for F1 score, the corresponding mean scores were 0.770 and 0.810 on images without and with site harmonization. In the CN group, it achieved lower F1 scores of 0.580 and 0.658 compared with 0.907 and 0.931 in the dementia group. We demonstrated that residual 3DCNN can learn complex 3D spatial patterns in FDG-PET images and robustly predict amyloid-β positivity with significantly less reliance on site harmonization preprocessing.

Background: Accurate lesion segmentation is critical for multiple sclerosis (MS) diagnosis, yet current deep learning approaches face robustness challenges. Aim: This study improves MS lesion segmentation by combining data fusion and deep learning techniques. Materials and Methods: We suggested novel radiomic features (concentration rate and R\'enyi entropy) to characterize different MS lesion types and fused these with raw imaging data. The study integrated radiomic features with imaging data through a ResNeXt-UNet architecture and attention-augmented U-Net architecture. Our approach was evaluated on scans from 46 patients (1102 slices), comparing performance before and after data fusion. Results: The radiomics-enhanced ResNeXt-UNet demonstrated high segmentation accuracy, achieving significant improvements in precision and sensitivity over the MRI-only baseline and a Dice score of 0.774$\pm$0.05; p<0.001 according to Bonferroni-adjusted Wilcoxon signed-rank tests. The radiomics-enhanced attention-augmented U-Net model showed a greater model stability evidenced by reduced performance variability (SDD = 0.18 $\pm$ 0.09 vs. 0.21 $\pm$ 0.06; p=0.03) and smoother validation curves with radiomics integration. Conclusion: These results validate our hypothesis that fusing radiomics with raw imaging data boosts segmentation performance and stability in state-of-the-art models.

Accurate segmentation and classification of brain tumors from Magnetic Resonance Imaging (MRI) remain key challenges in medical image analysis, largely due to the lack of high-quality, balanced, and diverse datasets. In this work, we present a new curated MRI dataset designed specifically for brain tumor segmentation and classification tasks. The dataset comprises 6,000 contrast-enhanced T1-weighted MRI scans annotated by certified radiologists and physicians, spanning three major tumor types-glioma, meningioma, and pituitary-as well as non-tumorous cases. Each sample includes high-resolution labels and is categorized across axial, sagittal, and coronal imaging planes to facilitate robust model development and cross-view generalization. To demonstrate the utility of the dataset, we propose a transformer-based segmentation model and benchmark it against established baselines. Our method achieves the highest weighted mean Intersection-over-Union (IoU) of 82.3%, with improvements observed across all tumor categories. Importantly, this study serves primarily as an introduction to the dataset, establishing foundational benchmarks for future research. We envision this dataset as a valuable resource for advancing machine learning applications in neuro-oncology, supporting both academic research and clinical decision-support development. datasetlink: https://www.kaggle.com/datasets/briscdataset/brisc2025/

Accurate diagnosis of brain disorders such as Alzheimer's disease and brain tumors remains a critical challenge in medical imaging. Conventional methods based on manual MRI analysis are often inefficient and error-prone. To address this, we propose DGG-XNet, a hybrid deep learning model integrating VGG16 and DenseNet121 to enhance feature extraction and classification. DenseNet121 promotes feature reuse and efficient gradient flow through dense connectivity, while VGG16 contributes strong hierarchical spatial representations. Their fusion enables robust multiclass classification of neurological conditions. Grad-CAM is applied to visualize salient regions, enhancing model transparency. Trained on a combined dataset from BraTS 2021 and Kaggle, DGG-XNet achieved a test accuracy of 91.33\%, with precision, recall, and F1-score all exceeding 91\%. These results highlight DGG-XNet's potential as an effective and interpretable tool for computer-aided diagnosis (CAD) of neurodegenerative and oncological brain disorders.